Evotec is a drug-discovery and development partner for pharmaceutical and biotech clients, offering end-to-end research from target identification through preclinical and early clinical work. Its platform spans small molecules, biologics and other modalities, with integrated discovery, manufacturing-related and data-driven services. The company is known for multi-year co-development and risk-sharing alliances rather than solely fee-for-service work, serving innovators that outsource R&D capacity.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 200 | — | -31.6 | — |
| Q2 2025 | 171.2 | — | -43.5 | — |
| Q3 2025 | 163.9 | — | -43.1 | — |
| Q4 2025 | 253.3 | — | 14.6 | — |
| Q1 2026 | 156.6 | -21.7% | -121.9 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: AngioDynamics, Inc. (ANGO), Oddity Tech Ltd. (ODD), MiMedx Group, Inc. (MDXG), ACNB Corporation (ACNB), Docebo Inc. (DCBO), Frequency Electronics, Inc. (FEIM)